Literature DB >> 10332977

Predominance of CD8+ T lymphocytes in psoriatic arthritis.

P Costello1, B Bresnihan, C O'Farrelly, O FitzGerald.   

Abstract

OBJECTIVE: To characterize the synovial fluid (SF) derived T cell populations in psoriatic arthritis (PsA) and compare with similar populations from rheumatoid arthritis (RA).
METHODS: Paired peripheral blood (PB) and SF samples were analyzed by 3 color flow cytometry using monoclonal antibodies to CD3, CD4, CD8, HLA-DR, CD25, CD45RA, and CD45RO.
RESULTS: There was a significantly increased CD8+ T cell population in PsA SF compared to RA: PsA mean 61% (range 35-93), RA mean 46% (range 6-72) (p < 0.005). This resulted in a reversal of the CD4:CD8 ratio in PsA SF compared to RA SF (p < 0.001). Patients with oligoarticular PsA had the most pronounced differences in SF derived T cell populations compared to RA (p < 0.0005) but these results were not significantly different from PsA patients with a polyarticular disease pattern. PB PsA T cell populations were not different from controls, in contrast to RA, where the CD4+ T cell population was increased (p < 0.0026), giving an exaggerated PB CD4:CD8 ratio. The majority of PsA SF CD8+ T cells expressed CD45RO, mean 73% (range 58-95), and HLA-DR antigen: mean 72% (range 38-94). Low levels of CD25 were detectable in this population, indicating a nonclassical activation pattern: mean 2% (range 0.3-4.4).
CONCLUSION: In PsA, activated (HLA-DR+) and mature (CD45RO+) CD8+ T cells predominate in SE Analysis of this population may uncover clues to pathogenesis in this HLA class I mediated disease.

Entities:  

Mesh:

Year:  1999        PMID: 10332977

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  36 in total

Review 1.  Disease mechanisms in psoriasis and psoriatic arthritis.

Authors:  P Costello; O FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

2.  Analysis of granulysin-mediated cytotoxicity in peripheral blood of patients with psoriatic arthritis.

Authors:  Drazen Massari; Larisa Prpic-Massari; Tatjana Kehler; Marija Kastelan; Bozidar Curkovic; Viktor Persic; Alen Ruzic; Gordana Laskarin
Journal:  Rheumatol Int       Date:  2011-08-10       Impact factor: 2.631

Review 3.  Role of IL-17 in psoriasis and psoriatic arthritis.

Authors:  Siba P Raychaudhuri
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

4.  PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation.

Authors:  Alessandra Petrelli; Gerdien Mijnheer; David P Hoytema van Konijnenburg; Maria M van der Wal; Barbara Giovannone; Enric Mocholi; Nadia Vazirpanah; Jasper C Broen; Dirkjan Hijnen; Bas Oldenburg; Paul J Coffer; Sebastian J Vastert; Berent J Prakken; Eric Spierings; Aridaman Pandit; Michal Mokry; Femke van Wijk
Journal:  J Clin Invest       Date:  2018-08-02       Impact factor: 14.808

5.  Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis.

Authors:  L Laloux; M C Voisin; J Allain; N Martin; L Kerboull; X Chevalier; P Claudepierre
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 6.  The History of Psoriatic Arthritis (PsA): From Moll and Wright to Pathway-Specific Therapy.

Authors:  Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2018-08-09       Impact factor: 4.592

Review 7.  CD8(+) T cells in human autoimmune arthritis: the unusual suspects.

Authors:  Alessandra Petrelli; Femke van Wijk
Journal:  Nat Rev Rheumatol       Date:  2016-06-03       Impact factor: 20.543

Review 8.  The IL-23-IL-17 axis in inflammatory arthritis.

Authors:  Erik Lubberts
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

Review 9.  New insights into the pathogenesis and genetics of psoriatic arthritis.

Authors:  Kristine E Nograles; Richard D Brasington; Anne M Bowcock
Journal:  Nat Clin Pract Rheumatol       Date:  2009-02

Review 10.  Treating psoriatic arthritis: how effective are TNF antagonists?

Authors:  Alice B Gottlieb; Christian E Antoni
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.